Obesity affects approximately 100 million Indian adults and is linked to over 200 health complications, including heart ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide ("FTS") rodent biodistribution study.

A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce federal regulations on compounded we ...

US giant, Eli Lilly launched Mounjaro (tirzepatide) which is a prescription medicine for adults with type 2 diabetes used ...

Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.

Copycat versions of Eli Lilly's diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They're still available on some websites.

Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...